Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2017) Moreau P, Miguel JS, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, et al. Journal article Prognostic factors for overall survival of patients with advanced renal cell carcinoma - data from the German prospective RCC-Registry (2017) Goebell P, Mueller L, Staehler M, Mueller M, Frank M, Kruggel L, Jaenicke M, Marschner N Conference contribution Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto) (2017) Untch M, Schneeweiss A, Salat C, Rezai M, Zahm DM, Klare P, Blohmer JU, et al. Conference contribution Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer (2017) Guarneri V, Fasching P, Fernandez Abad M, Garcia-Saenz A, Schneeweiss A, Colleoni M, Petru E, et al. Conference contribution Can contemporary trials in HER2-negative metastatic breast cancer (mBC) detect overall survival (OS) benefit? (2017) Kuemmel S, Jackisch C, Mueller V, Schneeweiss A, Klawitter S, Lux MP Conference contribution Treatment reality and outcome data of patients with advanced papillary renal cell carcinoma: Data from the German prospective RCC-Registry (2017) Staehler M, Mueller L, Goebell P, Overkamp F, Frank M, Kruggel L, Jaenicke M, Marschner N Conference contribution Interim results from PAZOREAL: A non-interventional study to assess effectiveness and safety of pazopanib and everolimus in the changing mRCC treatment landscape (2017) Bedke J, Welslau M, Boegemann M, Schostak M, Hering-Schubert C, Petzoldt A, Wolf T, et al. Conference contribution Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension (2017) Cwikla JB, Wolin EM, Pavel ME, Phan AT, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression (vol 25, pg 1551, 2014) (2017) Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, et al. Journal article Allogeneic Hematopoietic Cell Transplantation in Intermediate Risk Acute Myeloid Leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA Mutations (2017) Heidrich K, Thiede C, Schaefer-Eckart K, Schmitz N, Aulitzky WE, Kraemer A, Rösler W, et al. Journal article